Burton G. Malkiel

Burton G. Malkiel is a declared insider at 2 companies (board member); the most frequent names are Theravance Biopharma, Inc. and Innoviva, Inc. Over a trading history stretching from 22 April 2008 to 2 May 2023, the count stands at 21 filings.

The open-market record is one-sided, with 4 purchases worth €763k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 16 share grants.

In size, the median ticket on the buying side is €215k.

On 4 May 2023 came the latest disclosure, a share grant in Theravance Biopharma, Inc. The clock since the last published purchase (23 May 2018) now reads 3,092 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.